Cancer trial data mining: is time to next treatment a reliable shortcut?
NCT ID NCT03963518
First seen Oct 31, 2025 · Last updated May 02, 2026 · Updated 18 times
Summary
This study analyzed data from 631 cancer patients treated with immune-checkpoint inhibitors to see if the time until they needed a new treatment or died (TNT-D) could serve as a reliable substitute for overall survival in clinical trials. The research focused on previously untreated advanced melanoma patients. The goal was to determine if TNT-D could help speed up future trials by providing earlier results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER TREATED WITH IMMUNE-CHECKPOINT INHIBITORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Bergonié, Comprehensive Cancer Center
Bordeaux, France
Conditions
Explore the condition pages connected to this study.